ZA200802897B - New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease - Google Patents

New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease

Info

Publication number
ZA200802897B
ZA200802897B ZA200802897A ZA200802897A ZA200802897B ZA 200802897 B ZA200802897 B ZA 200802897B ZA 200802897 A ZA200802897 A ZA 200802897A ZA 200802897 A ZA200802897 A ZA 200802897A ZA 200802897 B ZA200802897 B ZA 200802897B
Authority
ZA
South Africa
Prior art keywords
pyrimidine derivatives
alzheimer
medicament
therapy
disease
Prior art date
Application number
ZA200802897A
Other languages
English (en)
Inventor
Andersson Lars
Berg Stefan
Hellberg Sven
Pedersen Torben
Rotticci Didier
Turek Dominika
Arzel Erwan
Burrows Jeremy
Huerta Fernando
Rein Tobias
Staaf Karin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200802897B publication Critical patent/ZA200802897B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200802897A 2005-10-03 2008-04-02 New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease ZA200802897B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0502174 2005-10-03

Publications (1)

Publication Number Publication Date
ZA200802897B true ZA200802897B (en) 2008-12-31

Family

ID=37906403

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200802897A ZA200802897B (en) 2005-10-03 2008-04-02 New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease

Country Status (20)

Country Link
US (1) US20090105252A1 (enExample)
EP (1) EP1945628A4 (enExample)
JP (1) JP2009513575A (enExample)
KR (1) KR20080059423A (enExample)
CN (1) CN101326179A (enExample)
AR (1) AR058073A1 (enExample)
AU (2) AU2006297890B2 (enExample)
BR (1) BRPI0616658A2 (enExample)
CA (1) CA2624875A1 (enExample)
EC (1) ECSP088405A (enExample)
IL (1) IL190150A0 (enExample)
NO (1) NO20082067L (enExample)
NZ (2) NZ566804A (enExample)
RU (2) RU2433128C2 (enExample)
SG (1) SG166125A1 (enExample)
TW (1) TW200800957A (enExample)
UA (1) UA92181C2 (enExample)
UY (1) UY29827A1 (enExample)
WO (1) WO2007040440A1 (enExample)
ZA (1) ZA200802897B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003208479A1 (en) 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200815417A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds II
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
WO2009017455A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
NZ590283A (en) * 2008-07-14 2012-11-30 Gilead Sciences Inc Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
NZ590320A (en) 2008-07-14 2012-12-21 Gilead Sciences Inc Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
WO2010033977A2 (en) 2008-09-22 2010-03-25 Cayman Chemical Company Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2419425A4 (en) * 2009-04-15 2012-08-29 Astrazeneca Ab IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE
GB0908772D0 (en) * 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
KR20120031170A (ko) 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 hdac 저해제 화합물
WO2012050517A1 (en) * 2010-10-14 2012-04-19 Astrazeneca Ab Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
EP3741375A1 (en) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
KR102342803B1 (ko) * 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
CA3172750A1 (en) * 2020-03-23 2021-09-30 Ge Hyeong Lee Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
TW202227401A (zh) * 2020-10-23 2022-07-16 大陸商重慶兩江藥物研發中心有限公司 用於持續釋放治療劑的前藥及其用途
JP7522315B2 (ja) * 2020-10-29 2024-07-24 蘇州亜宝薬物研発有限公司 置換ジアリールアミン化合物及びその医薬組成物、製造方法と用途
US20240239774A1 (en) * 2021-04-28 2024-07-18 Cornell University Soluble adenylyl cyclase (sac) inhibitors and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3530710A1 (de) 1985-08-28 1987-03-05 Hoechst Ag Verfahren zur herstellung von halogenphenyl-oxethyl-sulfiden und deren oxidationsprodukten
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
ES2316546T3 (es) * 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
SE0100569D0 (sv) * 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
EA007298B1 (ru) * 2001-11-01 2006-08-25 Янссен Фармацевтика Н.В. Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3)
AU2003208479A1 (en) * 2002-03-09 2003-09-22 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
WO2004072063A1 (en) * 2003-02-07 2004-08-26 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
WO2004083203A1 (en) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB0311276D0 (en) * 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
JP2007500178A (ja) * 2003-07-30 2007-01-11 サイクラセル・リミテッド プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
TW200528101A (en) * 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US7132651B2 (en) 2004-04-23 2006-11-07 Framatome Anp, Inc. In-situ BWR and PWR CRUD flake analysis method and tool
BRPI0614502A2 (pt) * 2005-07-30 2011-03-29 Astrazeneca Ab Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto
TW200815418A (en) * 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
EP2419425A4 (en) * 2009-04-15 2012-08-29 Astrazeneca Ab IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE

Also Published As

Publication number Publication date
TW200800957A (en) 2008-01-01
EP1945628A1 (en) 2008-07-23
EP1945628A4 (en) 2010-06-02
BRPI0616658A2 (pt) 2011-06-28
SG166125A1 (en) 2010-11-29
IL190150A0 (en) 2008-08-07
KR20080059423A (ko) 2008-06-27
UY29827A1 (es) 2007-05-31
NZ566804A (en) 2011-03-31
NZ591316A (en) 2012-06-29
AU2006297890B2 (en) 2011-04-28
WO2007040440A1 (en) 2007-04-12
AU2011200948A1 (en) 2011-03-24
AR058073A1 (es) 2008-01-23
AU2006297890A1 (en) 2007-04-12
CN101326179A (zh) 2008-12-17
NO20082067L (no) 2008-07-02
RU2433128C2 (ru) 2011-11-10
RU2008110910A (ru) 2009-11-10
JP2009513575A (ja) 2009-04-02
UA92181C2 (ru) 2010-10-11
ECSP088405A (es) 2008-05-30
US20090105252A1 (en) 2009-04-23
CA2624875A1 (en) 2007-04-12
RU2011115406A (ru) 2012-10-27

Similar Documents

Publication Publication Date Title
IL190150A0 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
EP1979324A4 (en) IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF COGNITIVE DISORDER, MORBUS ALZHEIMER, NEURODEGENERATION AND DEMENTIA.
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
IL191311A (en) Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury
HRP20130602T1 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EP2091566A4 (en) COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2083837T3 (pl) Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
IL185300A0 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
GB0410399D0 (en) The treatment of respiratory disease
GB0410398D0 (en) The treatment of respiratory disease
TWI369210B (en) Use of lgg in the manufacture of a medicament for the prevention or treatment of respiratory allergies
PL1670482T5 (pl) Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
LT1807156T (lt) Naujos farmacinės kompozicijos, naudingos nemigos gydyme
HK1120037A (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
HK1119947A (zh) 嘧啶衍生物在制造用於防止和/或治疗阿兹海默氏症的药物中的用途
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
ZA200804105B (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, Alzheimer's Disease, neurodegeneration and dementia